Biovica: Outlook for 2023 and 2024 - Redeye

Redeye updated our Biovica outlook after securing access to growth capital and initiating the US and European launch. The US direct sales progress is the essential value driver ahead. The US sales team has already activated DiviTum discussions with 150 of the most active US oncologists in this target market and most of the NCI Designated Cancer Centers. Our updated Base Case reflects a Base Case is SEK 29 with a Bull of SEK 60 and a Bear case of SEK 7.

Länk till analysen i sin helhet: https://www.redeye.se/research/893320/biovica-outlook-for-2023-and-2024?utm_source=finwire&utm_medium=RSS